Appendiceal goblet cell carcinomas have poor survival despite completion surgery

Purpose Appendiceal goblet cell carcinomas (aGCCs) are rare but aggressive tumours associated with significant mortality. We retrospectively reviewed the outcomes of aGCC patients treated at our tertiary referral centre. Methods We analysed aGCC patients, diagnosed between 1990–2016, assessing the impact of completion surgery and tumour factors on survival. Survival was assessed using Kaplan–Meier analysis. Results We identified 41 patients (23 F, 18 M); median age 61 (range 27–79) years. Mean tumour size was 10.5 (range 0.5–50) mm; most tumours were located in the appendiceal tip ( n = 18, 45%). Appendicectomy was the index surgery in 32 patients, 24 of whom subsequently underwent completion surgery at median 3 (range 1.3–13.3) months later. Histology from completion surgery showed residual disease in 8 patients: nodal disease ( n = 2) or residual tumour ( n = 6). Index surgery for the rest was either colectomy ( n = 7) or cytoreductive surgery plus intraperitoneal chemotherapy (CRS-HIPEC) ( n = 1). Index and completion surgery had 0% mortality and 2.5% morbidity. Overall and recurrence-free survival were not significantly affected by tumour grade or completion surgery. Disease recurred in 9 patients after a median follow-up of 57.0 (4.6–114.9) months; 7 of these patients died during follow-up. Recurrences were treated with CRS-HIPEC ( n = 1), palliative chemotherapy ( n = 3) or supportive care ( n = 5). Five- and ten- year overall survival were 85.3% and 62.3% respectively; 5-year and 10-year recurrence-free survival were 73.6% and 50.6%. Conclusion The prognosis of aGCCs remains relatively poor. Completion surgery did not prevent recurrence or improve survival, but this needs to be verified with a larger patient cohort. The high mortality associated with tumour recurrence questions current treatment recommendations.